Minodiab (Glipizide)

Glipizide, the active ingredient in Minodiab, is a sulfonylurea presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients by enhancing insulin secretion.

GNH USA supplies Minodiab as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Glipizide is a sulfonylurea used to manage hyperglycemia in type 2 diabetes.

- Type 2 diabetes mellitus: improves glycemic control by increasing endogenous insulin release. - Adjunct to diet and exercise: helps achieve target fasting and post‑prandial glucose levels. - Hyperglycemia: reduces elevated blood glucose concentrations when oral agents are required.

Glipizide may cause a range of adverse reactions, which are grouped by frequency and severity.

Common Side Effects: - Hypoglycemia: episodes of low blood sugar, especially if meals are missed. - Weight gain: modest increase in body weight due to enhanced insulin activity. - Nausea: mild gastrointestinal discomfort.

Serious or Rare Side Effects: - Severe hypoglycemia: prolonged or severe low blood sugar requiring medical attention. - Allergic reactions: rash, Stevens‑Johnson syndrome, or other severe skin manifestations. - Blood dyscrasias: leukopenia, thrombocytopenia, or other hematologic abnormalities.

When prescribing or dispensing Minodiab, several safety considerations are recommended.

- Blood glucose monitoring: check levels regularly to avoid hypoglycemia. - Renal impairment: dose may need adjustment in reduced kidney function. - Elderly patients: start with a lower dose and monitor closely. - Hepatic disease: use with caution in liver dysfunction. - Allergy: discontinue if hypersensitivity reactions occur. - Store at room temperature: keep in original container, protect from moisture and heat.

Glipizide can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Concurrent sulfonylureas or meglitinides: additive risk of hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone): increase glipizide plasma levels. - High‑dose aspirin: may potentiate hypoglycemic effect.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask symptoms of hypoglycemia. - Thiazide diuretics: can enhance hyperglycemic effect of glipizide. - Oral contraceptives: may alter glipizide metabolism.